174 related articles for article (PubMed ID: 15213712)
1. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer.
Miyazono F; Metzger R; Warnecke-Eberz U; Baldus SE; Brabender J; Bollschweiler E; Doerfler W; Mueller RP; Dienes HP; Aikou T; Hoelscher AH; Schneider PM
Br J Cancer; 2004 Aug; 91(4):666-72. PubMed ID: 15213712
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
[TBL] [Abstract][Full Text] [Related]
3. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
[TBL] [Abstract][Full Text] [Related]
4. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
6. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma.
Langer R; Specht K; Becker K; Ewald P; Bekesch M; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
Clin Cancer Res; 2005 Oct; 11(20):7462-9. PubMed ID: 16243820
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.
Aichler M; Motschmann M; Jütting U; Luber B; Becker K; Ott K; Lordick F; Langer R; Feith M; Siewert JR; Walch A
Oncotarget; 2014 Aug; 5(16):6620-32. PubMed ID: 25216514
[TBL] [Abstract][Full Text] [Related]
8. [Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis].
Langer R; Specht K; Becker K; Ewald P; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
Verh Dtsch Ges Pathol; 2004; 88():207-13. PubMed ID: 16892554
[TBL] [Abstract][Full Text] [Related]
9. Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.
Singh LC; Chakraborty A; Mishra AK; Devi TR; Sugandhi N; Chintamani C; Bhatnagar D; Kapur S; Saxena S
Med Oncol; 2012 Jun; 29(2):539-46. PubMed ID: 21528410
[TBL] [Abstract][Full Text] [Related]
10. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
[TBL] [Abstract][Full Text] [Related]
11. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
[TBL] [Abstract][Full Text] [Related]
12. Does neoadjuvant chemoradiation downstage esophageal carcinoma?
Slater MS; Holland J; Faigel DO; Sheppard BC; Deveney CW
Am J Surg; 2001 May; 181(5):440-4. PubMed ID: 11448438
[TBL] [Abstract][Full Text] [Related]
13. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
14. Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy.
Tanaka K; Mohri Y; Ohi M; Yokoe T; Koike Y; Morimoto Y; Miki C; Tonouchi H; Kusunoki M
Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):639-46. PubMed ID: 18691855
[TBL] [Abstract][Full Text] [Related]
15. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3.
Friess H; Fukuda A; Tang WH; Eichenberger A; Furlan N; Zimmermann A; Korc M; Büchler MW
World J Surg; 1999 Oct; 23(10):1010-8. PubMed ID: 10512940
[TBL] [Abstract][Full Text] [Related]
16. RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.
Denkert C; Loibl S; Kronenwett R; Budczies J; von Törne C; Nekljudova V; Darb-Esfahani S; Solbach C; Sinn BV; Petry C; Müller BM; Hilfrich J; Altmann G; Staebler A; Roth C; Ataseven B; Kirchner T; Dietel M; Untch M; von Minckwitz G
Ann Oncol; 2013 Mar; 24(3):632-9. PubMed ID: 23131391
[TBL] [Abstract][Full Text] [Related]
17. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.
Bollschweiler E; Hölscher AH; Herbold T; Metzger R; Alakus H; Schmidt H; Drebber U; Warnecke-Eberz U
Ann Surg; 2016 Nov; 264(5):839-846. PubMed ID: 27741011
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer.
Tanaka K; Otake K; Mohri Y; Ohi M; Yokoe T; Toiyama Y; Miki C; Tonouchi H; Kusunoki M
Oncol Rep; 2009 Jun; 21(6):1489-94. PubMed ID: 19424628
[TBL] [Abstract][Full Text] [Related]
19. The role of neoadjuvant radiochemotherapy using low-dose fraction cisplatin and 5-fluorouracil in patients with carcinoma of the esophagus.
Nakano S; Baba M; Natsugoe S; Kusano C; Shimada M; Fukumoto T; Aikou T
Jpn J Thorac Cardiovasc Surg; 2001 Jan; 49(1):11-6. PubMed ID: 11233236
[TBL] [Abstract][Full Text] [Related]
20. TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer.
Warnecke-Eberz U; Metzger R; Bollschweiler E; Baldus SE; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
Pharmacogenomics; 2010 Jan; 11(1):55-64. PubMed ID: 20017672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
